What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences

OBJECTIVE: The patent expiry of a number of biological medicines and the advent of biosimilars raised the expectations of healthcare commissioners that biosimilars would reduce the high cost of these medicines and produce potential savings to the NHS. We aimed to examine the prescribing pattern of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Stephen R, Fitzpatrick, Raymond W, Aladul, Mohammed I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541334/
https://www.ncbi.nlm.nih.gov/pubmed/28400458
http://dx.doi.org/10.1136/bmjopen-2016-013730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541334/
https://www.ncbi.nlm.nih.gov/pubmed/28400458
http://dx.doi.org/10.1136/bmjopen-2016-013730

Ejemplares similares